Investor Presentaiton
Investor Presentation
First nine months of 2018
Slide 4
Highlights - First nine months of 2018
Sales development
Sales decreased by 2% in Danish kroner and increased by 4% in local currencies to DKK 82.1 billion
International Operations sales increased by 2% in Danish kroner and grew by 8% in local currencies
.
.
North America Operations sales decreased by 6% in Danish kroner and increased by 1% in local currencies
The GLP-1 diabetes franchise increased by 18% in local currencies and accounted for 84% share of growth
Research and Development
Successful completion of additional three phase 3a trials with oral semaglutide; PIONEER 5, 8 and 10
Phase 1 trial initiated with OG2023SC, a novel oral GLP-1
Initiation of SELECT, a CVOT investigating efficacy of 2.4 mg subcutaneous semaglutide in people with overweight or obesity
Successful completion of phase 2 trial explorer5 with concizumab
Financials
Operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies to DKK 36.5 billion
Operating profit adjusted for severance costs related to lay-offs in Q3 2018 increased by 4% in local currencies
Net profit increased by 1% to DKK 30.1 billion and diluted earnings per share increased by 3% to 12.40 DKK per share
2018 financial outlook:
•
Sales growth is now expected to be 4-5% measured in local currencies (now around 4% lower reported)
Operating profit growth is still expected to be 2-5% measured in local currencies (still around 7% lower reported)
The 2018 share repurchase programme is increased by DKK 1.0 billion to DKK 15 billion due to higher free cash flow outlookView entire presentation